Table 3.
Attitudes and practices of PV and ADRs (n = 342).
| Attitudes | Number | (%) |
|---|---|---|
| Which method would you prefer to send ADRs information to an ADR reporting center? | ||
| Email/on Website | 164 | (49.4) |
| Direct contact | 120 | (36.1) |
| Telephone | 31 | (9.3) |
| Post | 12 | (3.6) |
| Other | 5 | (1.5) |
| Are you willing to implement ADRs reporting in your practice? | ||
| No | 39 | (11.4) |
| Yes | 302 | (88.6) |
| Should PV be taught in detail to HCP? | ||
| No | 23 | (6.7) |
| Yes | 319 | (93.3) |
| Practices | Number | (%) |
| Have you ever reported an ADR? | ||
| No | 249 | (73.2) |
| Yes | 91 | (26.8) |
| Have you ever identified an ADR in any Patients? | ||
| No | 107 | (31.6) |
| Yes | 232 | (68.4) |
| Number of identified ADRs in Patients | ||
| <5 | 98 | (42.6) |
| 5–10 | 64 | (27.8) |
| >10 | 68 | (29.6) |
PV: Pharmacovigilance; ADRs: Adverse Drug Reactions; HCP: Healthcare Professionals.
Numbers may not add to the total due to missing data.